In the phase 3 clinical trial, QuANTUM-First, to test the effect of quizartinib in combination with conventional chemotherapy in FLT3/ITD patients (NCT02668653), and the QuANTUM-R trial to compare quizartinib monotherapy vs. conventional salvage therapies among relapsed/refractory FLT3-ITD mutated patients (NCT02039726), the results showed a higher composite complete remission (CRc) rate in both older and younger patients with FLT3-ITD mutated relapsed/refractory AML (Stein and Tallman, 2016; Fathi and Chen, 2017; Saygin and Carraway, 2017). Here, FLT3 is linked to acute myeloid leukemia.